Pharmacovigilance in Middle East Conference

Similar documents
SOP Title: Reporting Adverse Events and New Safety Information

The New EU PV Legislation: View from the European Commission

Pharmacovigilance Office of Product Review

FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE

Corporate Induction: Part 2

Implementing Changes in Pharmacovigilance Regulations. Presented by Dr Ennis H Lee, Senior Partner, TranScrip 14 June 2016

Provided below is the background, discussion, and recommendations from the panelists.

Safeguarding public health. The New PV Legislation. Perspective from a Member State

Evaluating adverse events from patient support and market research programs: proposed best practices and regulatory changes

7 th European Forum for Qualified Person for Pharmacovigilance (QPPV)

Looking at our Achievements and the Way Forward. The 5 th pharmaceutical compliance congress & best practices forum Istanbul - Turkey

BETTER REGULATION OF MEDICINES INITIATIVE (BROMI): FIFTH REPORT ON PROGRESS

Issue 7/ Jul - Sept 2012

Safeguarding public health. The New PV Legislation its Impact on PV & MI

Postmarketing Drug Safety and Inspection Readiness

Information Brochure Professional Certificate in Pharmacovigilance

Good Pharmacovigilance Practice. Overview of GVP Modules on ADR, PSURs, Signal Management and Additional Monitoring Mick Foy - MHRA

Guidance notes for patient safety and pharmacovigilance in patient support programmes

Pharmacovigilance in Japan and Risk Management Plans(RMP); Regulator Perspective

The Pharmaceutical Risk Assessment Committee (PRAC) of the EMA

11 th Medication Safety Conference Programme 2018

Capturing the value of SCOPE to the EU Flagship Event London, 23 November 2016

MEDICATION SAFETY RESEARCH IN THE DIVISION OF SOCIAL PHARMACY, UNIVERSITY OF HELSINKI, FINLAND

WHO Pharmacovigilance Indicators. Dr. Nitin Gaikwad Co-coordinator, ADR Monitoring Center, PvPI Additional Professor, Pharmacology AIIMS Raipur

Pharmacovigilance documents in the life cycle of a medicinal product: DSUR, RMP, PSUR/PBRER, and Addendum to the Clinical Overview

9th Medication Safety Conference 4th - 6th November 2016, Jumeirah Etihad Towers, Abu Dhabi, UAE

Measures of impact of pharmacovigilance processes (3.3)

Pharmacovigilance assessor. National Institute of Pharmacy and Nutrition (OGYÉI) (Hungary) Senior hospital Pharmacist

Introduction to Post-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER

Benchmark. Middle East Hotel Benchmark Survey Report

Drug Safety Research Unit. DSRU Education & Training

Global Medical Safety Post-Doctoral Global Medical Safety (GMS) Fellowship

WHO Programme for International Drug Monitoring, Pharmacovigilance Centres & Patient Safety

Current status on Adverse Event Reporting in Japan

Legislations and Policies in Jordan/ Related to Health and Pharmaceuticals April 19, 2018

Healthcare Practice. Healthcare PanelBook 2017

Social Networks for Pharmacovigilance: different approaches for managing signals from ICRS to Twitter

8 th Medication Safety Conference 6 th - 8 th November 2015, Jumeirah Etihad Towers, Abu Dhabi, UAE

Benchmark. Middle East hotel benchmark survey report July 2015

Electronic submission of information on medicinal products in accordance to Article 57(2) requirements: Maintenance submission

Preview EUR PEAN PHARMACO VIGILANCE CONGRESS

MEDICINES CONTROL COUNCIL

Do you suffer from diabetes? Do you want to shape the future of diabetes care?

September 16 th, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

Pharmacovigilance & Managed Care Pharmacy. Issues for Medication Safety in Korea

Company Profile. Precision Surgical Instruments Manufacture and Supply

CLINICAL SERVICES OVERVIEW

Encouraging pharmacy involvement in pharmacovigilance; an international perspective.

Overview of Draft Pharmacovigilance Protocol

...FREEDOM TO EXPLORE YOUR REGULATORY NEEDS

Pharmacovigilance in Kenya

10 th Medication Safety Conference Programme 2017

Security and. Your Ultimate Arabic Language Source for Security and Defense News

Implementation of the new pharmacovigilance legislation: Overall update and activities in 2013

CURRENT PRACTICE OF PHARMACOVIGILANCE IN TANZANIA. Alex F. Nkayamba, MD. Officer, Clinical Trials and Pharmacovigilance Department

Pharmacovigilance and Risk Management Strategies Conference

Healthcare Opportunities

Teleconference Course Materials You may duplicate this for each person attending the conference.

Pharmacovigilance and Risk Management Strategies 2012

MEDICINES CONTROL COUNCIL

MEDICINES CONTROL COUNCIL

Benchmark. Middle East hotel benchmark survey report

Benchmark. Middle East hotel benchmark survey report

New Streams of Risk Management. Tomiko TAWARAGI Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA)

BUILDING QUALITY FOR SAFER HEALTHCARE An Integrated Approach Le Meridien Hotel Amman Jordan

Incident Investigation/ Root Cause Analysis Leadership

Title: A Blueprint for Outsourcing Audits of Approved GxP Validations

HAAD Guidelines for The Provision of Cardiovascular Disease Management Programs

CONTINUING PROFESSIONAL DEVELOPMENT (CPD) POLICY GUIDELINES

Strategies to Improve Medicine Use Drug and Therapeutics Committees

Advanced European Regulatory Affairs

Medicines Safety in WHO: promoting best practices in Pharmacovigilance

Adopted by Pharmacovigilance Risk Assessment Committee 20 February Adopted by Pharmacovigilance Inspectors Working Group 21 March 2014

10 th Medication Safety Conference Programme 2017

Health Authority Abu Dhabi Occupational and Environmental Health Section & The Safety in the Heat Programme

Clinical Research Professionals

PROGRAM INTERCHANGE Japan

Measuring Impact in Patient-Centered Drug Development Conference

Scope of Practice for Registered Nurses

Training & Resources for Clinical Research Professionals

In 2015, WHO intensified its support to Member

Table 1. Big Data Sources of Interest for Pharmacovigilance (PV)

Helping you capture new markets

Scope of Practice for Practical Nurses

1st Maghreb Regulatory Conference

GUIDELINES FOR CRITERIA AND CERTIFICATION RULES ANNEX - JAWDA Data Certification for Healthcare Providers - Methodology 2017.

DIA Brexit Summit Ensuring Continuity for Patients and Business

Nursing And Midwifery In The Eastern Mediterranean Region. Arwa Oweis Regional Adviser For Nursing, Midwifery and Allied Health Personnel

ACPE Standards for Continuing Pharmacy Education. Standard 1: Mission and Goals of CPE. Standard 1: Goal and Mission of the.

In 2012, the Regional Committee passed a

Standard Approaches to Adverse Event Reporting. Jonathan Deutsch, M.D.

A multi-ethnic multi-national approach to ethical approval of clinical trials involving Thalassaemia patients: the DEEP lesson. Prof.

Strengthening Collaborations for Operating Pharmacovigilance in Europe (SCOPE) Joint Action

ABDALLA IBRAHIM PATHWAY

Clinical Research Sites. Professionals

Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan

Applicant Kit. Your tool for a fast and easy application. Health Authority - Abu Dhabi (HAAD) DataFlow Verification Process

2017 Ambulatory Care Pharmacy Review and Recertification Course

THE FINTECH REGULATORY LABORATORY. The Regime For FinTech Innovation

CONTINUING PHARMACY EDUCATION (CPE) Project Planning Form for Live and Enduring Activities

Transcription:

Pharmacovigilance in Middle East Conference Target Audience: 20-21 January, 2012 Yas Rotana Hotel Abu Dhabi UAE HAAD Accredited for 7.25 CME Hours Regulatory Authorities; (Safety Programs, Regulatory affairs) Pharmacovigilance Solution/Systems/Technology Providers. Risk Management Consultants. Pharmaceutical Companies, CROs and Consultancy Firms ( Drug safety, Regulatory affairs, Medical affairs, Quality assurance, Safety process, Post-marketing surveillance, Signal detection, Patient safety, Data management, R&D) personnel for: (Pharmacovigilance, Medical monitoring, Drug safety project manager, Safety and risk management, Community Pharmacists, Clinical Pharmacists, Physicians) 1 st Day of the Conference; 20th January, 2012 7:30am - 8:30am 8:30am - 9:00am Registration HAAD Opening Remarks Dr.Mohammed Abuelkhair Head, Drug and Medical Product Regulation Section Health Authority-Abu Dhabi 9:00am - 9:30am Federal Pharmacovigilance Committee Speech Pharmacovigilance System in UAE. Dr.Amin Alameeri Asst.Undersecretary for Medical Practice and License (CEO) Ministry of Health, UAE

9:30am 10:00am Current Practice of PV in Abu Dhabi. Dr.Mohammed Abuelkhair Head, Drug and Medical Product Regulation Section Health Authority-Abu Dhabi 10:00am -10:30am 10:30am -11:00am Spontaneous reporting: Saudi Arabia Experience Expedited Reporting: Regulatory Perspective Definitions: ADEs, Serious events, unexpected events and serious Unexpected events. Backbone structure of ICSRs New Pharmacovigilance legislations Dr.Nasser AlQahtani Head, ADRs Evaluation Division Saudi Food and Drug Authority (SFDA) 11:00am -11:30am 11:30am -12:00 pm Break Periodic Safety Update Reports (PSUR) What is a PSUR Regulatory requirements for PSURs (International and in MENA) Differences in PSURs for Originators Vs Generics How to prepare a PSUR Dr.Lubna Rshaidat Regulatory Affairs Department Head Tabuk Pharmaceuticals-Jordan 12:00pm-01:45pm 01:45pm-02:30pm Friday Prayer & Lunch Risk management plans in PV To differentiate between risk management plans and risk minimization plans To outline the structure of RMP To have a background about the international requirements Dr.Adel Alrwisan Vigilance and Crisis Mangement Executetive Directorate Saudi FDA

02:30pm-03:15pm Global Networking in Pharmacovigilance. Progress in the PV scope Global system in PV Signal detection Dr.Amr Saad Head of the Egyptian pharmacovigilance Center EPVC 03:15pm-04:00pm Information Technology Systems in Pharmacovigilance. Mr.Subbaraju Sagi Managing Director Life & Health Sciences, TechSol & Robbert P. van Manen, M.Sc. Master Principal Sales Consultant Oracle Health Sciences 04:00pm-05:20pm Reporting Pharmacovigilance Profiles of different Medications (Workshop) Approved REMS plan for (Sitagliptin/metformin) Combination Bernd Voss Regional Director of Medical Affairs for Diabetes (Eastern Europe, Middle East, Africa) MSD RBSC in Munich, Germany 05:20pm-05:30pm Closing Remarks. End of the first day of the conference

2nd Day of the Conference; 21st January, 2012 08:00am-08:15am 08:15am-09:00am Opening the Second Day of the conference Training plans for PV Personnel Who can be a QPPV. What are the responsibilities of a QPPV. International Qualifying Training Courses. Dr.Mohammed Saleem Managing Director of SIPS SIPs, Jordan 09:00am-09:40am Medication Errors Reporting Define and categorize a medication error Report medication errors Investigate medication errors Dr.Adeline Saliba Acting Pharmacy Manager/Medication Safety Manager Al corniche Hospital 09:40am-10:00am Assessing your medication management system Benefits of assessing Recommended tools to assess your medication management system Developing action plans relevant to your assessment and defining priorities Dr.Lana Hammad Head of Pharmacy Department Al Rahba Hospital 10:00am-11:20am Reporting Pharmacovigilance Profiles of different Medications (Workshop) Romiplostim - Modified Nplate REMS program Dr. Tamer Saad Medical Director Amgen MEA Efficacy and safety of Dusasteride on management of benign prostatic hyperplasia

Dr. Essam Fikry Senior Medical Affairs Manager for Oncology and Urology GSK 11:20am-11:50am 11:50pm-01:50pm Break Developing Key Performance Indicators (Workshop) Should Key Performance Indicators for Clinical Services Be Mandatory Describe how to identify and select Key Performance Indicators (KPIs) that align with organizational needs Identifying your targets Define challenges in meeting your target Dr.Lana Hammad Head of Pharmacy Department Al Rahba Hospital 01:50pm-02:00pm Closing Remarks. Lunch End of the Second Day of the Conference